Lineage Cell Therapeutics, Inc. (LCTX) Total liabilities 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) total liabilities at each fiscal year-end, per SEC filings.
$69.2MFY2025 · since FY2016: $12.1M → $69.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $69.2M | +91.2% |
| FY2024 | $36.2M | -7.2% |
| FY2023 | $39.0M | -24.6% |
| FY2022 | $51.7M | -38.2% |
| FY2021 | $83.6M | +552.4% |
| FY2020 | $12.8M | -9.9% |
| FY2019 | $14.2M | +51.2% |
| FY2018 | $9.4M | +4.9% |
| FY2017 | $9.0M | -25.6% |
| FY2016 | $12.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice